A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  • End date
    Jan 31, 2024
  • participants needed
  • sponsor
Updated on 23 November 2020
AbbVie_Call Center
Primary Contact
BJC Health /ID# 223884 (6.8 mi away) Contact
+106 other location


Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. Despite the range of treatment options for RA steadily increasing, many patients remain sub-optimally managed, with sustained clinical remission rarely achieved. This study will assess the treatment patterns, achievement of treatment targets and maintenance of response.

Upadacitinib is a drug approved for the treatment of moderately to severely active rheumatoid arthritis. Adult participants with moderate to severe RA who have been prescribed upadacitinib by their physicians will be enrolled. Approximately, 1660 participants will be enrolled this study, worldwide.

Participants will not receive Upadacitinib as part of this study, but will be followed for response to treatment for up to 24 months.

There may be higher burden for participants in this trial compared to their standard of care. Participants will attend regular visits, every 3 months, during the course of the study at a hospital or clinic and will be asked to provide additional information by questionnaire at each visit.

Clinical Study IdentifierNCT04497597
Last Modified on23 November 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Rheumatoid Arthritis (Pediatric) or Rheumatoid Arthritis?
Do you have any of these conditions: Rheumatoid Arthritis or Rheumatoid Arthritis (Pediatric)?
Do you have any of these conditions: Rheumatoid Arthritis (Pediatric) or Rheumatoid Arthritis?
Confirmed diagnosis of moderate to severe active Rheumatoid Arthritis (RA)
Physician decision on patient treatment with upadacitinib must have been reached prior to and independently of recruitment in the study
Upadacitinib prescribed in accordance to the applicable approved label and local regulatory and reimbursement policies
French Participants Only: Taking oral glucocorticoids 5 mg/day of prednisone or equivalent for at least 3 months prior to study start

Exclusion Criteria

Prior treatment with Upadacitinib
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet